iTeos Therapeutics Announces Its Intention to Wind Down Operations
iTeos Therapeutics (NASDAQ: ITOS) has announced its intention to cease operations and wind down its business activities. The company's Board of Directors has made this decision following a comprehensive review of its development pipeline, business prospects, and financial position. iTeos will focus on maximizing shareholder value through potential sales of its intellectual property and assets, including:
- EOS-984
- EOS-215
- A preclinical obesity program targeting ENT1
The clinical-stage biopharmaceutical company, which specializes in immuno-oncology therapeutics, will concentrate on leveraging its cash balance to deliver near-term value to shareholders through these potential asset sales.
iTeos Therapeutics (NASDAQ: ITOS) ha annunciato la sua intenzione di cessare le operazioni e chiudere le attività aziendali. Il Consiglio di Amministrazione della società ha preso questa decisione dopo una revisione approfondita del suo portafoglio di sviluppo, delle prospettive di business e della situazione finanziaria. iTeos si concentrerà sulla massimizzazione del valore per gli azionisti attraverso potenziali vendite della proprietà intellettuale e degli asset, tra cui:
- EOS-984
- EOS-215
- Un programma preclinico per l'obesità mirato a ENT1
La società biofarmaceutica in fase clinica, specializzata in terapie immuno-oncologiche, si focalizzerà sull'utilizzo del saldo di cassa per offrire valore a breve termine agli azionisti tramite queste potenziali vendite di asset.
iTeos Therapeutics (NASDAQ: ITOS) ha anunciado su intención de cesar operaciones y liquidar sus actividades comerciales. El Consejo de Administración de la empresa tomó esta decisión tras una revisión exhaustiva de su pipeline de desarrollo, perspectivas comerciales y situación financiera. iTeos se enfocará en maximizar el valor para los accionistas mediante posibles ventas de su propiedad intelectual y activos, incluyendo:
- EOS-984
- EOS-215
- Un programa preclínico para la obesidad dirigido a ENT1
La compañía biofarmacéutica en fase clínica, especializada en terapias de inmuno-oncología, se centrará en aprovechar su saldo de efectivo para ofrecer valor a corto plazo a los accionistas a través de estas posibles ventas de activos.
iTeos Therapeutics (NASDAQ: ITOS)는 사업 운영을 중단하고 사업 활동을 종료할 의사를 발표했습니다. 회사 이사회는 개발 파이프라인, 사업 전망 및 재무 상태에 대한 종합적인 검토 후 이 같은 결정을 내렸습니다. iTeos는 다음과 같은 지적 재산권 및 자산의 잠재적 매각을 통해 주주 가치를 극대화하는 데 집중할 예정입니다:
- EOS-984
- EOS-215
- ENT1을 표적으로 하는 전임상 비만 프로그램
임상 단계 바이오제약 회사로서 면역항암 치료제를 전문으로 하는 iTeos는 현금 잔고를 활용하여 이러한 잠재적 자산 매각을 통해 단기적으로 주주에게 가치를 제공하는 데 주력할 것입니다.
iTeos Therapeutics (NASDAQ : ITOS) a annoncé son intention de cesser ses activités et de liquider ses opérations. Le conseil d'administration de la société a pris cette décision après un examen approfondi de son pipeline de développement, de ses perspectives commerciales et de sa situation financière. iTeos se concentrera sur la maximisation de la valeur pour les actionnaires grâce à la vente potentielle de sa propriété intellectuelle et de ses actifs, notamment :
- EOS-984
- EOS-215
- Un programme préclinique sur l'obésité ciblant ENT1
Cette société biopharmaceutique en phase clinique, spécialisée dans les thérapies d'immuno-oncologie, mettra à profit sa trésorerie pour offrir une valeur à court terme aux actionnaires à travers ces potentielles ventes d'actifs.
iTeos Therapeutics (NASDAQ: ITOS) hat seine Absicht bekannt gegeben, den Geschäftsbetrieb einzustellen und die Geschäftstätigkeiten abzuwickeln. Der Vorstand des Unternehmens hat diese Entscheidung nach einer umfassenden Überprüfung der Entwicklungspipeline, der Geschäftsaussichten und der finanziellen Lage getroffen. iTeos wird sich darauf konzentrieren, den Aktionärswert durch potenzielle Verkäufe seines geistigen Eigentums und seiner Vermögenswerte zu maximieren, darunter:
- EOS-984
- EOS-215
- Ein präklinisches Adipositas-Programm mit Ziel ENT1
Das biopharmazeutische Unternehmen in der klinischen Phase, das sich auf Immunonkologie-Therapeutika spezialisiert hat, wird seine Barbestände nutzen, um den Aktionären durch diese potenziellen Vermögensverkäufe kurzfristig Wert zu bieten.
- Potential value creation through sale of intellectual property and assets
- Company still has cash balance to support wind-down operations
- Early decision to wind down may help preserve shareholder value versus continuing operations
- Complete cessation of business operations
- Discontinuation of all clinical and operational activities
- Potential loss of jobs and intellectual capital
- Uncertainty regarding the final value shareholders will receive
- Board of Directors intends to cease operations
- Company to focus efforts on selecting best path to deliver near-term value to shareholders
- Exploring potential asset sales including EOS-984, EOS-215, and a preclinical obesity program targeting ENT1
WATERTOWN, Mass. and GOSSELIES, Belgium, May 28, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the intention to wind down its operations as part of a comprehensive review of strategic alternatives aimed at maximizing shareholder value.
Following a thorough assessment of the Company’s development pipeline, business prospects, and financial position, the Company’s Board of Directors intends to wind down clinical and operational activities and focus on leveraging the Company’s cash balance to deliver near-term value to shareholders, including any proceeds from the potential sale of the Company’s intellectual property and assets such as EOS-984, EOS-215, and a preclinical obesity program targeting ENT1.
About iTeos Therapeutics, Inc.
iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of tumor immunology and immunosuppressive pathways to design novel product candidates with the potential to restore the immune response against cancer. iTeos Therapeutics is headquartered in Watertown, MA with a research center in Gosselies, Belgium.
Forward-Looking Statements
This press release contains forward-looking statements. Any statements that are not solely statements of historical fact are forward-looking statements. Words such as “believe,” “anticipate,” “plan,” “expect,” “will,” “may,” “intend,” “prepare,” “look,” “potential,” “possible” and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements relating to iTeos’ intention to wind down clinical and operational activities and focus its efforts on selecting the best path to deliver near-term value to shareholders, including by leveraging its cash balance and potentially selling EOS-984, EOS-215 and a preclinical obesity program targeting ENT1.
These forward-looking statements involve risks and uncertainties, many of which are beyond iTeos’ control. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: risks relating to whether iTeos will be able to effectively wind down its operations and return capital to shareholders; and those risks identified under the heading “Risk Factors” in iTeos’ Annual Report on Form 10-K for the period ended December 31, 2024 filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by iTeos which you are encouraged to review.
Any of the foregoing risks could materially and adversely affect iTeos’ business, results of operations and the trading price of iTeos’ common stock. We caution investors not to place undue reliance on the forward-looking statements contained in this press release. iTeos does not undertake any obligation to publicly update its forward-looking statements other than as required by law.
For further information, please contact: Investor Contact: Carl Mauch iTeos Therapeutics, Inc. carl.mauch@iteostherapeutics.com Media Contact: media@iteostherapeutics.com
FAQ
Why is iTeos Therapeutics (ITOS) shutting down operations?
What assets is ITOS planning to sell?
What will happen to ITOS shareholders after the wind-down?
Will ITOS continue any clinical trials?
What happens to ITOS stock during a company wind-down?
